Anavex Life Sciences (AVXL) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 26.7% versus a loss of 85.4%. Over five years, AVXL leads with a -92.7% price change compared with -99.9% for HURA. Anavex Life Sciences is the larger company by market cap ($121.4 million vs $112.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | HURA |
|---|---|---|
| Share price | $1.31 | $1.76 |
| Market cap | $121.43M | $112.16M |
| 1-day change | -11.49% | -3.83% |
| YTD return | -63.20% | +132.50% |
| 1-year return | -85.41% | -26.67% |
| 5-year return | -92.66% | -99.89% |
| EPS (TTM) | $-0.14 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-46.38M | $-30.05M |
| 52-week high | $9.50 | $3.43 |
| 52-week low | $1.30 | $0.41 |
| Distance from 52-week high | -86.21% | -48.69% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +356.82% |
| Average volume | 1.01M | 221.74K |
| Shares outstanding | 92.70M | 63.73M |
| Employees | 34 | 22 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed AVXL by 58.7 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Healthcare · Biotechnology · 34 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Healthcare · Biotechnology · 22 employees
AVXL vs HURA FAQ
Which is bigger, Anavex Life Sciences or TuHURA Biosciences?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $121.43M compared with $112.16M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, AVXL or HURA?
HURA returned -26.67% over the past 12 months, compared with -85.41% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.